Vorasidenib Significantly Improved Progression-free Survival Compared to the Placebo
In a critical advancement for the treatment of IDH-mutant grade 2 gliomas, a recent double-blind, phase 3 trial has evaluated the efficacy of vorasidenib, an oral inhibitor of mutant IDH1 and IDH2 enzymes. The study focused on patients with residual or recurrent grade 2 IDH-mutant glioma who had not undergone previous treatment other than surgery, and the results shed light on the potential of vorasidenib in improving progression-free survival and delaying the time to the next intervention.
- Participants: 331 patients with residual or recurrent grade 2 IDH-mutant glioma, no previous treatment other than surgery.
- Intervention: Random assignment to receive either oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles.
- Primary End Point: Imaging-based progression-free survival.
- Secondary End Point: Time to the next anticancer intervention.
- Safety Assessment: Included in the study design.
- Progression-Free Survival: Significantly improved in the vorasidenib group (median 27.7 months) compared to the placebo group (11.1 months); hazard ratio 0.39; 95% CI, 0.27 to 0.56; P<0.001.
- Time to Next Intervention: Significantly improved in the vorasidenib group; hazard ratio, 0.26; 95% CI, 0.15 to 0.43; P<0.001.
- Adverse Events: Grade 3 or higher in 22.8% of vorasidenib patients and 13.5% of placebo patients; increased alanine aminotransferase level of grade 3 or higher in 9.6% of vorasidenib patients.
- Vorasidenib significantly improved progression-free survival and delayed the time to the next intervention in patients with grade 2 IDH-mutant glioma.